533 related articles for article (PubMed ID: 19571771)
1. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
[TBL] [Abstract][Full Text] [Related]
2. CDKN2A mutations in multiple primary melanomas.
Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
[TBL] [Abstract][Full Text] [Related]
3. Multiple primary melanoma revisited.
Blackwood MA; Holmes R; Synnestvedt M; Young M; George C; Yang H; Elder DE; Schuchter LM; Guerry D; Ganguly A
Cancer; 2002 Apr; 94(8):2248-55. PubMed ID: 12001124
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
5. Role of the CDKN2A locus in patients with multiple primary melanomas.
Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
[TBL] [Abstract][Full Text] [Related]
6. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
7. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
8. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
Smith SA; Richards WE; Caito K; Hanjani P; Markman M; DeGeest K; Gallion HH
Gynecol Oncol; 2001 Dec; 83(3):586-92. PubMed ID: 11733976
[TBL] [Abstract][Full Text] [Related]
10. Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland.
Debniak T; van de Wetering T; Scott R; Nagay L; Cybulski C; Górski B; Jakubowska A; Gronwald J; Masojć B; Huzarski T; Byrski T; Nej-Wołosiak K; Kładny J; Maleszka R; Lubinski J
Eur J Cancer Prev; 2008 Oct; 17(5):389-91. PubMed ID: 18714178
[TBL] [Abstract][Full Text] [Related]
11. A common variant of CDKN2A (p16) predisposes to breast cancer.
Debniak T; Górski B; Huzarski T; Byrski T; Cybulski C; Mackiewicz A; Gozdecka-Grodecka S; Gronwald J; Kowalska E; Haus O; Grzybowska E; Stawicka M; Swiec M; Urbański K; Niepsuj S; Waśko B; Góźdź S; Wandzel P; Szczylik C; Surdyka D; Rozmiarek A; Zambrano O; Posmyk M; Narod SA; Lubinski J
J Med Genet; 2005 Oct; 42(10):763-5. PubMed ID: 15879498
[TBL] [Abstract][Full Text] [Related]
12. BRCA2 germline mutations in primary cancer of the fallopian tube.
Casarsa S; Puglisi F; Baudi F; De Paola L; Venuta S; Piga A; Di Loreto C; Marchesoni D; D'Elia AV; Damante G
Oncol Rep; 2004 Aug; 12(2):313-6. PubMed ID: 15254695
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
[TBL] [Abstract][Full Text] [Related]
14. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
[TBL] [Abstract][Full Text] [Related]
15. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
16. Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer.
Sugano K; Nakamura S; Ando J; Takayama S; Kamata H; Sekiguchi I; Ubukata M; Kodama T; Arai M; Kasumi F; Hirai Y; Ikeda T; Jinno H; Kitajima M; Aoki D; Hirasawa A; Takeda Y; Yazaki K; Fukutomi T; Kinoshita T; Tsunematsu R; Yoshida T; Izumi M; Umezawa S; Yagata H; Komatsu H; Arimori N; Matoba N; Gondo N; Yokoyama S; Miki Y
Cancer Sci; 2008 Oct; 99(10):1967-76. PubMed ID: 19016756
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.
Lang J; Boxer M; MacKie RM
Br J Dermatol; 2005 Dec; 153(6):1121-5. PubMed ID: 16307646
[TBL] [Abstract][Full Text] [Related]
19. CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma.
Blokx WA; Lesterhuis WJ; Andriessen MP; Verdijk MA; Punt CJ; Ligtenberg MJ
Am J Surg Pathol; 2007 Apr; 31(4):637-41. PubMed ID: 17414113
[TBL] [Abstract][Full Text] [Related]
20. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
